Krystal Biotech: Blockbuster Ambitions For Topical Gene Therapy
Portfolio Pulse from
Krystal Biotech's VYJUVEK, a gene therapy for DEB, achieved $83.8M in Q3 2024 sales, doubling from Q4 2023. Despite a high P/E ratio, earnings are expected to double by 2025. Expansion into EU and Japan markets could drive further growth.
December 27, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Krystal Biotech's VYJUVEK sales reached $83.8M in Q3 2024, doubling from Q4 2023. The stock trades at a high P/E ratio but is expected to double earnings by 2025. Expansion into EU and Japan markets could lead to significant growth.
The significant increase in VYJUVEK sales and the potential for market expansion into the EU and Japan suggest strong growth prospects for Krystal Biotech. Despite a high P/E ratio, the projected doubling of earnings by 2025 indicates potential for stock price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100